



ABN: 97 084 464 193

Suite 1 A, Level 2
802 Pacific Highway
Gordon NSW 2072

P: +61 2 9844 5422
F: +61 2 9844 5445



**Australian Securities Exchange Limited
Companies Announcements Office
SYDNEY**

30 October 2012

EXTRA ORDINARY GENERAL MEEING

Bioxyne Limited (ASX: BXN) advises that the resolutions were carried by way of poll at today's Extraordinary General Meeting.

Bioxyne CEO David Radford said, "We thank our loyal shareholders for their support and look forward to progressing our commercialisation strategy with renewed confidence and focus.

As a result of the decision of members at today's meeting, Mr Jeremy Curnock Cook and Mr Glenn Crisp will leave the Board. This follows the earlier decision of Dr Doug Wilson to leave the Board last week.

The Company expects to announce the results of its strategic review of its operations prior to the AGM to be held in Sydney on 29 November 2012, which will lead to further changes.

Bioxyne acknowledges the contribution of the retiring Directors and is pleased to record that Mr Crisp will continue in a professional capacity to provide support for the Company

Results of poll and resolutions

The Results of the poll on each resolution are provided in the attached letter from the polling officer.

For Further information please contact:

David Radford
Chief Executive Officer
Tel: +61 (0) 407-218-922

Tim Allerton or Andrew Geddes
CityPR
(02) 9267 4511



ABN: 97 084 464 193

Suite 1 A, Level 2
802 Pacific Highway
Gordon NSW 2072

P: +61 2 9844 5422
F: +61 2 9844 5445



About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology. The Company's lead therapy, HI-164OV is based on the Company's proprietary technology that uses the application of mucosal immunology to treat common human diseases. HI-164OV works by controlling bacterial infections of airways damaged by toxins. The global incidence of COPD, which includes common

diseases like bronchitis and emphysema, is growing rapidly and is a substantial burden on health budgets. Bioxyne also makes and sells consumer food supplements, based on a proprietary probiotic compound, generating a source of revenues. For further information please visit www.bioxyne.com

COPD

Chronic Obstructive Pulmonary Disease (COPD) is a disease largely caused by smoking but with a rising number of new cases caused by pollution in developing countries like China and India. The global demand for COPD treatments is growing rapidly with an analysis by the Australian Lung Foundation in 2008 indicating the wide economic cost of to the Australian economy in 2010 was estimated to be \$9 billion in direct and indirect costs, with \$1 billion incurred in direct health system expenditure. There are currently no effective treatments for COPD and 25 per cent of COPD patients admitted to hospital die within one year. Reducing hospital admissions is crucial and preventing exacerbations is the main choice of therapy. More than 15 per cent of new patients have never smoked and

Industrial pollution is viewed as a major risk factor in the onset of COPD. It is estimated COPD will be third leading cause of mortality in the next decade, behind heart failure and cancer.

30 October 2012

The Chairman
Bioxyne Limited
Suite 1A, Level 2
802 Pacific Highway
Gordon NSW 2072

Poll Report

I, the Returning Officer appointed by you in connection with the voting by poll on the motion set out below at the Extraordinary General Meeting of the Members of Bioxyne Limited held at the Institute of Chartered Accountants, Burke & Wills room, Level 9, 33 Erskine Street, Sydney NSW 2000 on 30 October 2012 at 12:00 PM, report as follows:

1) Removal of Mr Ian Mutton as Director

	Number	%
Votes cast 'FOR' the motion	57,028,753	45.96
Votes cast 'AGAINST' the motion	67,050,898	54.04
TOTAL VOTES CAST	124,079,651	100.00
Votes "Abstained"	1,538,003	

The resolution was not carried as an ordinary resolution.

2) Removal of Mr David Radford as Director

	Number	%
Votes cast 'FOR' the motion	58,714,302	46.80
Votes cast 'AGAINST' the motion	66,735,349	53.20
TOTAL VOTES CAST	125,449,651	100.00
Votes "Abstained"	158,003	

The resolution was not carried as an ordinary resolution.

3) Election of Dr Stewart James Washer as Director

	Number	%
Votes cast 'FOR' the motion	57,567,106	45.88
Votes cast 'AGAINST' the motion	67,893,290	54.12
TOTAL VOTES CAST	125,460,396	100.00
Votes "Abstained"	157,984	

The resolution was not carried as an ordinary resolution.

4) Removal of Dr Jeremy Curnock Cook as Director

	Number	%
Votes cast 'FOR' the motion	66,693,367	53.16
Votes cast 'AGAINST' the motion	58,766,284	46.84
TOTAL VOTES CAST	125,459,651	100.00
Votes "Abstained"	158,003	

The resolution was carried as an ordinary resolution.

5) Removal of Dr Douglas Wilson as Director

The resolution was withdrawn.

6) Removal of Mr Glenn Crisp as Director

	Number	%
Votes cast 'FOR' the motion	63,859,790	51.04%
Votes cast 'AGAINST' the motion	<u>61,262,889</u>	<u>48.96%</u>
TOTAL VOTES CAST	<u>125,122,679</u>	<u>100.00</u>
Votes "Abstained"	494,975	

The resolution was carried as an ordinary resolution.

7) Election of Mr Anthony Ho as Director

	Number	%
Votes cast 'FOR' the motion	77,297,189	61.60
Votes cast 'AGAINST' the motion	<u>48,188,207</u>	<u>38.40</u>
TOTAL VOTES CAST	<u>125,485,396</u>	<u>100.00</u>
Votes "Abstained"	132,984	

The resolution was carried as an ordinary resolution.



Helen Potbury
Returning Officer
Computershare Investor Services Pty Limited